{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:21:30Z","timestamp":1791602490607,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.tox.2010.10.006","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T04:46:36Z","timestamp":1288068396000},"page":"10-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies"],"prefix":"10.1016","volume":"279","author":[{"given":"David E.","family":"Amacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2010.10.006_bib0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1006\/faat.1997.2389","article-title":"Tetracycline-induced steatosis in primary canine hepatocyte cultures","volume":"40","author":"Amacher","year":"1997","journal-title":"Fundam. Appl. Toxicol."},{"key":"10.1016\/j.tox.2010.10.006_bib0010","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1753425908094718","article-title":"Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes","volume":"14","author":"Bartolom\u00e9","year":"2008","journal-title":"Innate Immun."},{"key":"10.1016\/j.tox.2010.10.006_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"10.1016\/j.tox.2010.10.006_bib0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hep.23271","article-title":"Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease","volume":"51","author":"Bell","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0025","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/S0016-5085(98)70590-6","article-title":"Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes","volume":"114","author":"Berson","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tox.2010.10.006_bib0030","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.22569","article-title":"Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression","volume":"48","author":"Cheung","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-12927","article-title":"Etiopathogenesis of nonalcoholic steatohepatitis","volume":"21","author":"Chitturi","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tox.2010.10.006_bib0040","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/clinchem\/34.5.890","article-title":"Valproic acid and the liver","volume":"34","author":"Cotariu","year":"1988","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tox.2010.10.006_bib0045","first-page":"95","article-title":"Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells","volume":"2","author":"Cui","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.tox.2010.10.006_bib0050","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tox.2010.10.006_bib0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gut.2003.024935","article-title":"Cytokines and the pathogenesis of non-alcoholic steatohepatitis","volume":"54","author":"Diehl","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.tox.2010.10.006_bib0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cbi.2009.07.019","article-title":"Cytometric analysis for drug-induced steatosis in HepG2 cells","volume":"181","author":"Donato","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tox.2010.10.006_bib0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/hep.21530","article-title":"Nonalcoholic fatty liver sensitizes rats to carbon tetrachloride hepatotoxicity","volume":"45","author":"Donthamsetty","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0070","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1097\/SLA.0b013e3181bcd6dd","article-title":"Assessment of hepatic steatosis by expert pathologists: the end of a gold standard","volume":"250","author":"El-Badry","year":"2009","journal-title":"Ann. Surg."},{"key":"10.1016\/j.tox.2010.10.006_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","article-title":"miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting","volume":"3","author":"Esau","year":"2006","journal-title":"Cell Metab."},{"issue":"2 Suppl. 1","key":"10.1016\/j.tox.2010.10.006_bib0080","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/ar.20715","article-title":"Hepatic microcirculation in fatty liver disease","volume":"291","author":"Farrell","year":"2008","journal-title":"Anat. Rec. (Hoboken)"},{"key":"10.1016\/j.tox.2010.10.006_bib0090","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/hep.23050","article-title":"Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study","volume":"50","author":"Feldstein","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0095","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0022-3565(25)22984-6","article-title":"Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice","volume":"255","author":"Fromenty","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tox.2010.10.006_bib0100","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0163-7258(95)00012-6","article-title":"Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity","volume":"67","author":"Fromenty","year":"1995","journal-title":"Pharmacol. Ther."},{"issue":"Suppl. 2","key":"10.1016\/j.tox.2010.10.006_bib0105","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(97)80496-5","article-title":"Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines","volume":"26","author":"Fromenty","year":"1997","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tox.2010.10.006_bib0110","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jat.1420","article-title":"In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis","volume":"29","author":"Fujimura","year":"2009","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.tox.2010.10.006_bib0115","doi-asserted-by":"crossref","first-page":"G592","DOI":"10.1152\/ajpgi.00063.2005","article-title":"Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production","volume":"289","author":"Grefhorst","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.tox.2010.10.006_bib0120","first-page":"261","article-title":"Fatty liver and drugs","volume":"9","author":"Grieco","year":"2005","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.tox.2010.10.006_bib0125","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1194\/jlr.M600148-JLR200","article-title":"Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver","volume":"47","author":"Gudbrandsen","year":"2006","journal-title":"J. Lip. Res."},{"key":"10.1016\/j.tox.2010.10.006_bib0130","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/837419","article-title":"Inflammatory mediators of hepatic steatosis","author":"Hijona","year":"2010","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.tox.2010.10.006_bib0135","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3748\/wjg.v16.i12.1495","article-title":"Biochemical determination of lipid content in hepatic steatosis by the Soxtec method","volume":"16","author":"Hijona","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tox.2010.10.006_bib0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2337\/db09-0016","article-title":"Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance","volume":"59","author":"Huang","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.tox.2010.10.006_bib0145","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2559.2006.02416.x","article-title":"Histological assessment of non-alcoholic fatty liver disease","volume":"49","author":"H\u00fcbscher","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.tox.2010.10.006_bib0150","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/toxsci\/65.2.166","article-title":"Mechanisms of hepatotoxicity","volume":"65","author":"Jaeschke","year":"2002","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2010.10.006_bib0155","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/bit.22191","article-title":"Development of an in vitro cell culture model of hepatic steatosis using hepatocyte-derived reporter cells","volume":"102","author":"Janorkar","year":"2009","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.tox.2010.10.006_bib0160","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1365-2036.2007.03586.x","article-title":"Adipokines and cytokines in non-alcoholic fatty liver disease","volume":"27","author":"Jarrar","year":"2008","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.tox.2010.10.006_bib0165","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.1840200440","article-title":"The Mallory body: morphological, clinical and experimental studies (Part 1 of a literature survey)","volume":"20","author":"Jensen","year":"1994","journal-title":"Hepatology"},{"issue":"Suppl. 2","key":"10.1016\/j.tox.2010.10.006_bib0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/01926230490451699","article-title":"Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression","volume":"32","author":"Jolly","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.tox.2010.10.006_bib0175","article-title":"Plasma metabolomic profile in nonalcoholic fatty liver disease","author":"Kalhan","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/j.tox.2010.10.006_bib0180","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1007\/s10620-008-0535-0","article-title":"Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis","volume":"54","author":"Kayadibi","year":"2009","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.tox.2010.10.006_bib0185","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1055\/s-0029-1240005","article-title":"The pathology of drug-induced liver injury","volume":"29","author":"Kleiner","year":"2009","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tox.2010.10.006_bib0190","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0195","first-page":"192","article-title":"Histopathologic changes associated with fialuridine hepatotoxicity","volume":"10","author":"Kleiner","year":"1997","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.tox.2010.10.006_bib0200","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00365520903443852","article-title":"Serum chemerin and vaspin in non-alcoholic fatty liver disease","volume":"45","author":"Kukla","year":"2010","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.tox.2010.10.006_bib0205","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ab.2004.04.043","article-title":"Determination of prolidase activity using matrix-assisted laser desorption\/ionization time-of-flight mass spectrometry","volume":"331","author":"Kurien","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.tox.2010.10.006_bib0210","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1472-8206.2008.00608.x","article-title":"Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies","volume":"22","author":"Labbe","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2010.10.006_bib0215","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1124\/jpet.106.114546","article-title":"Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver","volume":"321","author":"Larosche","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tox.2010.10.006_bib0220","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1373\/clinchem.2009.131797","article-title":"Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury","volume":"55","author":"Laterza","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.tox.2010.10.006_bib0225","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.taap.2007.09.014","article-title":"Subchronic effects of valproic acid on gene expression profiles for lipid metabolism in mouse liver","volume":"226","author":"Lee","year":"2008","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2010.10.006_bib0230","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1096\/fj.04-3196com","article-title":"Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis","volume":"19","author":"Lettiott","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.tox.2010.10.006_bib0235","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(96)80030-4","article-title":"Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice","volume":"24","author":"Lett\u00e9ron","year":"1996","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tox.2010.10.006_bib0240","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/jhep.2003.50309","article-title":"Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice","volume":"38","author":"Lett\u00e9ron","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0046-8177(90)90076-H","article-title":"Histopathologic analysis of suspected amiodarone hepatotoxicity","volume":"21","author":"Lewis","year":"1990","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tox.2010.10.006_bib0250","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1148\/rg.295085186","article-title":"Imaging-based quantification of hepatic fat: methods and clinical applications","volume":"29","author":"Ma","year":"2009","journal-title":"Radiographics"},{"key":"10.1016\/j.tox.2010.10.006_bib0255","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1440-1746.2008.05731.x","article-title":"The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease","volume":"24","author":"Malik","year":"2009","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tox.2010.10.006_bib0260","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/109793301753407948","article-title":"Nile red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis","volume":"14","author":"McMillian","year":"2001","journal-title":"In Vitro Mol. Toxicol."},{"key":"10.1016\/j.tox.2010.10.006_bib0265","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1021\/tx060007f","article-title":"Identification of early proteomic markers for hepatic steatosis","volume":"19","author":"Meneses-Lorente","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2010.10.006_bib0270","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1111\/j.1572-0241.2007.01520.x","article-title":"Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD)","volume":"102","author":"Mishra","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.tox.2010.10.006_bib0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11894-009-0083-6","article-title":"Nontriglyceride hepatic lipotoxicity: the new paradigm for the pathogenesis of NASH","volume":"12","author":"Neuschwander-Tetri","year":"2010","journal-title":"Curr. Gastroenterol. Rep."},{"key":"10.1016\/j.tox.2010.10.006_bib0280","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.23719","article-title":"Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites","volume":"52","author":"Neuschwander-Tetri","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0285","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2214\/ajr.180.1.1800129","article-title":"Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy","volume":"180","author":"Nishino","year":"2003","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.tox.2010.10.006_bib0290","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.etp.2007.05.009","article-title":"Regenerative capacity differs between micro- and macrovesicular hepatic steatosis","volume":"59","author":"Oleszczuk","year":"2007","journal-title":"Exp. Toxicol. Pathol."},{"key":"10.1016\/j.tox.2010.10.006_bib0295","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.2174\/092986706778521878","article-title":"Current pharmacological treatment of nonalcoholic fatty liver","volume":"13","author":"Portincasa","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.tox.2010.10.006_bib0300","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00000441-200511000-00012","article-title":"Hepatic cirrhosis caused by low-dose oral amiodarone therapy","volume":"330","author":"Puli","year":"2005","journal-title":"Am. J. Med. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.tox.2010.10.006_bib0305","first-page":"33","article-title":"Predictors of nonalcoholic steatohepatitis in patients with elevated alanine aminotransferase activity","volume":"34","author":"Puljiz","year":"2010","journal-title":"Coll. Antropol."},{"key":"10.1016\/j.tox.2010.10.006_bib0310","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1055\/s-0029-1240011","article-title":"Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use","volume":"29","author":"Raja","year":"2009","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tox.2010.10.006_bib0315","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/jcp.2008.058248","article-title":"Histological patterns in drug-induced liver disease","volume":"62","author":"Ramachandran","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.tox.2010.10.006_bib0320","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/gast.2001.27126","article-title":"Nonalcoholic steatohepatitis","volume":"121","author":"Reid","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tox.2010.10.006_bib0325","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.tiv.2008.05.009","article-title":"Steatohepatitis-inducing drugs trigger cytokeratin cross-links in hepatocytes. Possible contribution to Mallory-Denk body formation","volume":"22","author":"Robin","year":"2008","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.tox.2010.10.006_bib0330","first-page":"1","article-title":"The perils of fatty liver disease","volume":"36","author":"Rollins","year":"2010","journal-title":"Clin. Lab. News"},{"key":"10.1016\/j.tox.2010.10.006_bib0335","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1055\/s-2001-12933","article-title":"Fatty liver in liver transplantation and surgery","volume":"21","author":"Selzner","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tox.2010.10.006_bib0340","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.mam.2007.09.014","article-title":"Mitochondrial involvement in non-alcoholic steatohepatitis","volume":"29","author":"Serviddio","year":"2008","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.tox.2010.10.006_bib0345","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/hep.23337","article-title":"Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity","volume":"51","author":"Stienstra","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0350","doi-asserted-by":"crossref","unstructured":"Stravitz, R.T., Sanyal, A.J., 2003. Drug-induced steatohepatitis. Clin. Liver Dis. 7, 435\u2013451.","DOI":"10.1016\/S1089-3261(03)00027-8"},{"key":"10.1016\/j.tox.2010.10.006_bib0355","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1872-034X.2009.00615.x","article-title":"Identification of a novel biomarker for oxidative stress induced by hydrogen peroxide in primary human hepatocytes using the 2-nitrobenzenesulfenyl chloride isotope labeling method","volume":"40","author":"Takami","year":"2010","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.tox.2010.10.006_bib0360","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.gcb.2009.05.009","article-title":"Liver biopsy in alcoholic and non-alcoholic steatohepatitis patients","volume":"33","author":"Tiniakos","year":"2009","journal-title":"Gastroenterol. Clin. Biol."},{"key":"10.1016\/j.tox.2010.10.006_bib0365","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.1073\/pnas.0813371106","article-title":"Circulating microRNAs, potential biomarkers for drug-induced liver injury","volume":"106","author":"Wang","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tox.2010.10.006_bib0370","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/cr.2009.73","article-title":"Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells","volume":"19","author":"Wobser","year":"2009","journal-title":"Cell Res."},{"key":"10.1016\/j.tox.2010.10.006_bib0375","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/labinvest.2010.75","article-title":"Blockade of interleukin-6 signaling enhances hepatic steatosis but improves liver injury in methionine choline-deficient diet-fed mice","volume":"90","author":"Yamaguchi","year":"2010","journal-title":"Lab. Invest."},{"key":"10.1016\/j.tox.2010.10.006_bib0380","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.tox.2010.10.006_bib0390","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1471-230X-8-53","article-title":"Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH)","volume":"8","author":"Yoneda","year":"2008","journal-title":"BMC Gastroenterol."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X10005305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X10005305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:14:14Z","timestamp":1759533254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X10005305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":77,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0300483X10005305"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2010.10.006","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2010.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}